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Abstract An invitational expert meeting on indicators of
prescribing quality was held on 13–15 May 2004,
bringing together—from 19 European countries, the US,
Canada, and Australia—40 researchers specialized in the
development and application of indicators. The meeting
was organized by the European Drug Utilization
Research Group (EuroDURG), the Belgian National
Health Insurance Institute (RIZIV-INAMI), and the
World Health Organisation Regional Oﬃce for Europe
(WHO-Euro). The ﬁeld of prescribing quality was
deﬁned and delineated from the medical error ﬁeld. A
conceptual grid for classifying quality indicators was
discussed, combining two axes (a drug/disease/patient
axis and a structure/process/outcome axis). In addition,
available databases were listed for continuous monitor-
ing of drug utilization in Europe, with a description of
the content and the richness of the collected data, as well
as the impact on the potential and limitations to develop
quality indicators. The importance of the origin of data
for validity assessment was stressed, as data on drug
utilization may originate from physician sources (pre-
scribing data), from pharmacist or health insurer sources
(distribution data), or directly from patient sources
(compliance data). The diﬀerent aspects of validity and
their methods of assessment were listed. An overview of
the (in)appropriate uses of indicators was given. The
state of the art of the development and application of
prescribing quality indicators in all represented countries
was made, together with a ﬁrst draft of a database of
prescribing quality indicators, already subjected to val-
idation procedures.
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Introduction
An expert meeting on indicators of prescribing quality
was organised in Mechelen, Belgium on 13–15 May
2004, in a joint eﬀort of the European Drug Utilization
Research Group (EuroDURG), the Belgian National
Health Insurance Institute (RIZIV-INAMI), and the
World Health Organisation Regional Oﬃce for Europe
(WHO-Euro).
In past decades, most European countries have
developed data collection systems to monitor drug util-
isation by measuring volume and expenditures of med-
icines on a national scale. For international
comparisons, a drug classiﬁcation system was elaborated
by the World Health Organisation, namely the Ana-
tomical Therapeutic and Chemical Classiﬁcation with
standardisation of the expression of drug consumption
in Deﬁned Daily Doses (the ATC/DDD system) [1]. A
number of transnational studies comparing volume and
expenditures of diﬀerent countries have been published,
culminating in recent pan-European comparisons [2, 3,
4]. Meanwhile, national drug utilisation monitoring
systems have been increasingly used for measuring not
only volume and expenditures of prescribing, but also
the quality of prescribing. Hence, it is now time to pay
attention to the opportunities and pitfalls in measuring
prescribing quality using indicators derived from drug
utilisation databases.
The Expert Meeting was labeled DURQUIM (Drug
Utilisation Research Quality Indicators Meeting). From
The DURQUIM Scientiﬁc Committee: Andersen M, Bergman U,
Chapman S, de Joncheere CP, De Swaef A, Elsevier MM, Haaijer-
Ruskamp FM, Hallas J, Mol PG, Vander Stichele RH, Vlahovic V,
Wettermark B.
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meeting, all of whom were researchers and/or policy-
makers involved in speciﬁc European programs for
quality indicator development. Three observers were
present from the US, Canada and Australia.
The meeting focussed on four issues: a taxonomy of
prescribing quality indicators, types of available data
sources for working with indicators, the validity of
indicators, and the possible (in)appropriate uses of
prescribing quality indicators. Another objective of the
meeting was to start a European catalogue of drug
utilisation databases and of currently used prescribing
quality indicators, including the status of validation of
these indicators.
The meeting was prepared by a Scientiﬁc Committee
and the Department of Clinical Pharmacology of the
University of Groningen (The Netherlands), resulting in
a background paper, with a complete literature review
and a description of the ‘‘state of the art’’. This docu-
ment is now available as a World Health Organisation
publication [5].
At the start of the meeting, a representative of every
country gave a short overview of data sources and
examples of prescribing indicators available in his/her
country (see EuroDURG web site http://www.eurodurg.
com). These presentations clearly illustrated the existing
diﬀerences among European countries. Then, the four
major themes of the meeting were discussed. An intro-
duction was given for each of the themes, followed by an
intense group discussion in small working groups and a
plenum. Experts from the US, Canada and Australia in-
formed the group on speciﬁc projects abroad. In a closing
session, a proposal for methodological and policy rec-
ommendations was reﬁned and ﬁnalised (see Annex 1).
A taxonomy of quality indicators of prescribing
This ﬁrst theme was introduced by F.M. Haaijer-
Ruskamp (Clinical Pharmacology, University of Gron-
ingen, The Netherlands).
The proposal for a taxonomy is based on the deﬁni-
tion of prescribing quality, as agreed on by the WHO:
‘‘rational drug use means each patient receiving medi-
cation appropriate for his/her clinical needs, in doses
meeting the related requirements, for an adequate period
of time and at the lowest costs to them and to the
community,’’ with the element of including the patient’s
perspective as proposed by Barber [6, 7]. The deﬁnition
of a prescribing quality indicator was given adjusted
from the general indicator of quality of care, described
by Lawrence and Olesen (1997): ‘‘a measurable element
of prescribing performance for which there is evidence
or consensus that it can be used to assess quality, and
hence in changing the quality of care provided’’ [8].
Based on this deﬁnition, a taxonomy grid was pro-
posed to categorize prescribing quality indicators, sub-
divided in process and outcome indicators on a ﬁrst axis
and on a second drug-, disease-, and patient axis. Drug-
oriented indicators include information solely on drugs.
Disease-oriented indicators include information on
drugs linked to diagnosis, where prescribing quality is
seen as a part of the treatment quality. Patient-oriented
indicators include information on individual clinical
characteristics of the patient, e.g., severity of the disease.
In a third separate axis, indicators can be included that
describe documentation requirements, such as docu-
mentation of drug allergy on the medical chart.
It was proposed to limit the taxonomy to prescribing
decisions and to include some aspects of medication
error (limited to prescribing an inappropriate medicine,
over- and under dosage, as well as suboptimal pre-
scribing such as not prescribing an indicated medicine).
Some problem areas were discussed such as the use of
indicator sets as opposed to individual indicators and
the inclusion of patient preference into prescribing. Also,
the diﬀerence between a prescribing quality indicator
and a comparator was emphasized; the latter is used to
compare prescribing patterns at diﬀerent levels, doctors,
regions, countries, etc.
The nature of the available data sources
This second theme was introduced by J. Hallas (Clinical
Pharmacology, Odense University, Denmark).
He emphasized the importance of using accurate
data, i.e., the internal validity, and stressed the impor-
tance of recognizing the origin of the data, by proposing
a grid along the lines of the prescribing and drug util-
isation process: prescribing data (stemming from general
practitioner databases); dispensing/purchasing/reim-
bursement data (stemming from pharmacy databases);
and data on actual ingestion of medicines (stemming
from patient observations).
Areas of major and minor uncertainty exist at all
levels of the prescribing process. Discrepancy between
diﬀerent data sources was illustrated as well as its con-
sequence for the use of quality indicators with examples
derived from scientiﬁc literature. Lack of information on
actual drug intake was considered a major problem. In
general, the choice of the optimal data set is determined
mainly by the problem studied. Is it the prescribing
process? If so, GP data often provides the most complete
information since these databases include information
on the diagnosis. Is it drug exposure? If so, a pharmacy
database may be better, although information on actual
drug intake or health outcome requires information
from the patient.
Validation of quality indicators of prescribing
M. Andersen (General Practice, University of Southern
Denmark, Denmark) introduced this third theme.
He pointed out the necessity of having valid indi-
cators and explained the concept of external validity. In
the context of quality indicators, the concept of external
832validity demands evidence that the indicator is a good
translation of the actual clinical situation or problem
under study, and that changes in the value of the indi-
cator are indeed related to changes in health. Diﬀerent
types of external validity were discussed, i.e., face-,
content-, concurrent and construct validity. Deﬁnitions
were given and further elucidated with examples to
demonstrate the need for proper validation. To date,
attention to validity has focused on content- and face
validity. The few examples that have looked at concur-
rent validity indicate that content- and face validity
may not be adequate, especially when indicating pre-
scribing quality of complex diseases such as asthma. For
adequate validity of indicators, involvement of stake-
holders, in particular prescribers and patients, is
important.
The use of quality indicators of prescribing
The last theme was introduced by S. Chapman (Medi-
cines Management, Keele University, UK).
The essential issue in using indicators is asking the
right questions with the right data and for the right
reasons. In the UK, routinely available PACT (primary
care alliance for clinical trials) data give information on
expenditures and volume trends over time and are used
to support GPs, to contain expenditures, for bench-
marking and for identifying outliers. Issues of volume
and expenditures are most often the primary focus,
although they indicate little about prescribing quality.
One of the problems is that PACT data lack information
on diagnosis or indication. However, combining PACT
data with data from a GP database, such as GPRD
(General Practice Research Database), gives opportu-
nities for more detailed prescribing quality measure-
ment. Chapman identiﬁed barriers to Europe-wide
indicators and wondered which minimum standards
with regard to prescribing quality indicators could be
applied across Europe.
Summing up
Prof. J. Avorn (Harvard Medical School, Boston, USA)
discussed the meeting results from an American view-
point. He presented the RAND template for rational
prescribing. This template uses the ‘‘if (health prob-
lem)—then (drug)—because (clinical trial data)’’ terms to
identify the underlying logic of a prescription. Avorn
concluded with a two-sided implementation of quality
indicators, through educational outreach and political
buy-in (see Euro DURG Web site).
Information on Australian projects was brought by
Jane Robertson. Colleen Metge reported on the Cana-
dian experiences.
The participants concluded the meeting by stressing
the relevance of developing European indicators of
prescribing quality to be based on international
evidence. Such European indicators are valuable in
identifying the main problems in prescribing within the
European countries. Shared problem areas, such as the
use of cardiovascular drugs, antibiotics, and anti-asth-
matics should be used as a focus in developing Europe-
wide indicators.
The meeting ended with a set of recommendations,
supported by the participants, on the four aspects of
quality indicators discussed. These recommendations
focus on methodological aspects and on policy making
(see Annex 1)
It was decided that, in the following years, this
meeting on quality indicators in general will be followed
by a number of meetings on speciﬁc drug classes, such as
cardiovascular drugs, antibiotics, and anti-asthmatics.
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Annex 1: Recommendations of the drug utilisation
research quality indicator meeting (DURQUIM), held in
Mechelen, Belgium, 13–15 May 2004
Recommendations on methodology
On taxonomy it is recommended
– To deﬁne a prescribing quality indicator as a mea-
surable element of prescribing performance for which
there is evidence or consensus that it can be used to
assess quality and, hence, be used in changing the
quality of care provided
– To adopt and test a taxonomy in research programs
categorizing indicators as drug-, disease-, and patient-
oriented indicators of prescribing quality at process
and outcome level for quality indicator development
– To develop indicators of prescribing quality
– To develop disease-oriented quality indicators
– To develop indicators that include the patient
preference
On the use of databases, it is recommended
– To be conscious and explicit about limitations of data
sources.
– To conduct comparative studies on speciﬁc prescrib-
ing quality indicators within data sources on diﬀerent
levels (physician, pharmacy and patient).
– To develop a catalogue of all available databases
within Europe. In particular, the availability of clini-
cal data and treatment objectives must be considered.
– To further explain the use and ownership of such a
database.
833On the validity it is recommended
– To consider validation as an integral part of the
development and implementation of indicators
– To consider requirements on validity in relation to the
type of indicator (taxonomy) and the purpose it is
used for (context)
– To provide an explicit and clear evidence base, e.g.,
what part of the guidelines is referred to and the ex-
tent the guidelines are up to date (content validity)
– To assess consensus procedures in relevant target
groups, both in development and validation of indi-
cators (face validity)
– To compare indicators of prescribing quality with
another (gold) standard for both disease- and patient–
oriented indicators, especially if indicators include
proxies of indications, co-morbidity, or disease
severity (concurrent validity)
– To start with a catalogue of prescribing indicators
used across Europe with information on validation,
use and references to guidelines, studies, and reports
On the use of indicators, it is recommended
– To have common standards of data collection
– To have common general principles for generating
indicators
– To have common evidence base for quality indicators
on all levels (individual to national)
– That in most cases quality indicators need informa-
tion on drug as well as diagnosis or indication
Recommendations on policy
On taxonomy it is recommended
– To include or develop indicators of prescribing quality
– To include both drug- and disease-oriented quality
indicators
– To promote development of disease-oriented quality
indicators
– To support the development and implementation of a
robust and valid methodology to select prescribing
quality indicators
– To harmonise the development and/or inclusion of
indicators of prescribing quality in sets of performance
indicators
On databases it is recommended
– To organise and maintain a catalogue of major data
sources across Europe, using EURO-MEDSTAT as a
starting point
– To use a common form for description of databases
– To facilitate access to and linkage between relevant
data sources
– To strengthen existing administrative drug databases
on volume and expenditures by supplementing with
clinical data and/or a clinical database from a
population sample
On use of indicators it is recommended
– To measure prescribing quality in key disease areas on
a national level and to empower prescribers
– To diﬀerentiate between quality indicators and com-
parators (relative markers)
– To let quality indicators lead to a payback to
healthcare systems, either in saving money or better
health.
– To share individual country-generated indicators
when in context
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